Regorafenib in Patients with Solid Tumors: Results from the TAPUR Study

Chemistry, Medicinal Chemistry, Medicine, Medical Laboratory Science, Oncology, Life Sciences, Immunology,
Regorafenib   BRAF alterations   tumors   antitumor activity   TAPUR study  

The Use of Regorafenib in Patients with BRAF-Mutant Solid Tumors: A Summary of Results from the TAPUR Study Background Introduction The BRAF gene belongs to the cytoplasmic serine/threonine kinase family and regulates cell proliferation and survival by activating the mitogen-activated protein kinase signaling pathway (MAPK). BRAF mutations can lead...

D3S-001: A KRAS G12C Inhibitor with Rapid Target Engagement Kinetics, Overcomes Nucleotide Cycling, and Demonstrates Robust Preclinical and Clinical Activities

Medicine, Basic Medical Sciences, Oncology,
D3S-001   KRAS G12C   inhibitor   nucleotide cycling   clinical activity   antitumor activity  

D3S-001, a KRAS G12C Inhibitor with Rapid Target Engagement Kinetics, Inhibits Nucleotide Cycling and Demonstrates Robust Preclinical and Clinical Activity Background Introduction The KRAS (Kirsten rat sarcoma viral oncogene homolog) gene mutation is one of the oncogenic drivers in various solid tumors (such as non-small cell lung cancer (NSCLC) an...